Navigation Links
hKvLQT1/hminK-CHO K1 Recombinant Cell Line from Upstate

ProductshKvLQT1/hminK-CHO K1 Recombinant Cell Line from Upstate
Company Upstate
Item hKvLQT1/hminK-CHO K1 Recombinant Cell Line
Price 
Description PrecisION Ion Channel Cell Lines
High Quality, Functionally-Validated, Ion Channel Cell Lines

Ion channels are well known for having a critical role in nerve and muscle function and consequently have a key function in pain, CNS and the heart. Drugs that modulate ion channels have been investigated in therapeutic areas, such as neuropathic pain, cardiac arrhythmia, hypertension, local anaesthesia, stroke, Parkinson's, obesity, epilepsy, diabetes and depression.

Historically, ion channels have been under exploited as drug targets primarily due to the lack of functional high throughput screening technologies. Over recent years, there has been considerable progress in this important area. However, now there is a requirement for high quality research tools that will allow the full benefit of the new screening technologies to be realised. Upstate has built a portfolio of ion channel cell lines to meet these new and evolving needs in the drug discovery industry.

Our ion channel cell lines are available off of the shelf. These cell lines are fully validated using electrophysiology, stable (>25 passage) and licensed for drug discovery research. The objective is to provide the pharmaceutical industry with a range of ion channel cell lines to support drug discovery, lead optimisation and safety pharmacology functions.
Info UpstateUpstate
28820 Single Oak Drive
Temecula, CA 92590
Customer Service: 800-437-7500 or 951-676-8080
Tech Support: 800 548-7853
Fax Number: 800-437-7502 or 951-676-9209
Web Site: http://www.upstate.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Recombinant Expression of Peptides and Proteins: from rPeptide, LLC
2. Recombinant RNasin® Ribonuclease Inhibitor from Promega
3. GeneChoice RNA Safe Recombinant Ribonuclease Inhibitor from GeneChoice, Inc.
4. RNaseOUT Recombinant Ribonuclease Inhibitor from Invitrogen
5. hKv4.2/hKChIP2-CHO K1 Recombinant Cell Line from Upstate
6. hERG-CHO K1 Recombinant Cell Line from Upstate
7. hERG-CHO K1 Recombinant Cell Line from Upstate
8. hHCN4-CHO K1 Recombinant Cell Line from Upstate
9. hKv1.5-CHO K1 Recombinant Cell Line from Upstate
10. hNav1.6-HEK293 Recombinant Cell Line from Upstate
11. Smac/DIABLO, Human, Recombinant, E. coli from Calbiochem
Anti-TWIK-1 Immunogen: Purified peptide from amino acids 53-69 of human TWIK-1 (Accession number O00180)....
EDG-6 (1)...
RAW; Collected from 8-12 week old sexually mature mice that are free of common parasites; RAW Collected from 8-12 week old sexually mature mice that are free of common parasites....
Ras-related C3 botulinum toxin substrate 1...
Biology Products:
(Date:1/23/2017)... , Jan. 23, 2017  The latest mobile ... smartphone prices have dropped dramatically. The quarterly average price ... 2013 to $276 in Q4 2016.  There are now ... price of $116, up from just 28 a year ... According to Maxine Most , Acuity Market ...
(Date:1/19/2017)... 19, 2017 Sensory Inc ., ... security for consumer electronics, and i ... and cybersecurity solutions, today announced a global partnership ... institutions worldwide to bolster security of data sensitive ... user authentication platforms they offer, innerCore now offers ...
(Date:1/13/2017)... , Jan. 13, 2017 Sandata Technologies, ... for the homecare industry, including Electronic Visit Verification™ ... expert, Justin Jugs, as Senior Vice President of ... 15 years of homecare experience to Sandata, where ... strategic plans to align Sandata,s suite of solutions ...
Breaking Biology News(10 mins):
(Date:2/18/2017)... -- Research and Markets has announced the addition of ... their offering. ... The report provides separate comprehensive analytics for the US, ... World. Annual estimates and forecasts are provided for the period 2015 ... markets. Market data and analytics are derived from primary and secondary ...
(Date:2/17/2017)... 2017  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today ... peptide drug candidates, PTG-100 and PTG-200, at the ... and Colitis Organization (ECCO).  The ECCO congress is ... from February 15 – 18, 2017. ... Protagonist drug candidates PTG-100 and PTG-200. PTG-100, a ...
(Date:2/16/2017)... Fla. , Feb. 16, 2017  MDNA ... revolutionizing the development of liquid biopsy tests based ... entered into an exclusive license agreement with its ... MDNA,s proprietary liquid biopsy test for prostate cancer, ... South Korea . This is the first ...
(Date:2/16/2017)... , February 16, 2017 ... the infusion of innovative telemedicine application, new and ... that are experiencing a boom worldwide. The healthcare ... advancement of technologies, services and new therapies for ... RQHTF) (TSX-V: RHT), Cellectar Biosciences, Inc. (NASDAQ: ...
Breaking Biology Technology: